CONCORD BIOTECH
Back to Balance Sheet
|
CONCORD BIOTECH Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹37 Cr | ₹32 Cr | ₹32 Cr | ₹54 Cr | ₹77 Cr |
What is the latest Total Non-Current Liabilities ratio of CONCORD BIOTECH ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹37 Cr |
| Mar2024 | ₹32 Cr |
| Mar2023 | ₹32 Cr |
| Mar2022 | ₹54 Cr |
| Mar2021 | ₹77 Cr |
How is Total Non-Current Liabilities of CONCORD BIOTECH Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹37 Cr | 17.43 | |
| Mar2024 | ₹32 Cr | -0.71 | |
| Mar2023 | ₹32 Cr | -40.93 | |
| Mar2022 | ₹54 Cr | -29.74 | |
| Mar2021 | ₹77 Cr | - | |
Compare Total Non-Current Liabilities of peers of CONCORD BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CONCORD BIOTECH | ₹13,036.8 Cr | -4.7% | -7.1% | -41.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹391,488.0 Cr | -2.5% | -7% | -8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,415.0 Cr | -2.2% | -7.2% | 1.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹132,906.0 Cr | -4% | 2.8% | 27.1% | Stock Analytics | |
| CIPLA | ₹106,210.0 Cr | -5.5% | -12.4% | -5.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,089.0 Cr | 5.9% | -3.7% | -6.5% | Stock Analytics | |
CONCORD BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD BIOTECH | -4.7% |
-7.1% |
-41.8% |
| SENSEX | -2.4% |
-4.7% |
6.4% |
You may also like the below Video Courses